Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sex Differences in Deep Brain Stimulation Implants, Management and Levodopa Adjustments in Two Population-based Parkinsonism Cohorts in Minnesota
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
111
To assess sex differences in deep brain stimulation (DBS) voltage, number of voltage adjustments, Levodopa doses, and survival in two population-based incident cohorts of parkinsonism.
No previous studies have addressed sex differences in DBS management in a population-based cohort of parkinsonism.
We used the Rochester Epidemiology Project (REP) to explore a population-based parkinsonism cohort between 1991-2005 in Olmsted County, MN. We extended to the 6 surrounding counties between 2010-2015 using the expanded REP (eREP) to identify all incident cases of early-onset parkinsonism (diagnosis before 55 years of age). A movement disorder specialist reviewed all medical records to confirm the diagnoses of Parkinson’s disease (PD).

We found 20 (15 in the first cohort and 5 in the second) PD patients that underwent DBS implantation (12 men and 8 women). Median age at DBS implantation was 58.3 years (IQR: 54.7-63.1) in men and 68.8 (IQR: 60.2-76.2) in women (p= 0.11). Median electrodes voltage was 2.91 V (IQR: 2.08-3.05) in men and 2.15 V (IQR: 2.04-2.31) in women (p= 0.32), with a median number of adjustments of 5 (IQR: 3.75-7.00) in men and 4.5 (IQR: 2.75-6.5) in women (p= 0.67).

Median daily dose of Levodopa was higher in men (1200 mg, IQR: 1050-1600) compared to women (500 mg, IQR: 450-700), (p= 0.004).

Six (30%) were deceased at data collection. These included one man, who died at 66.4 years of age (7.9 years after DBS implantation) and 5 women (median age of death was 81 years (IQR: 75.6-82.5), 4.3 years after DBS implantation, IQR 3.3-6.0).

Among the 20 DBS-PD cases, men underwent DBS implantation 10 years earlier than women. Men also required higher electrode voltages, more voltage adjustments and higher Levodopa doses (p= 0.004). These findings suggest that men may have a greater disease severity at the time of DBS implantation.
Authors/Disclosures
Emanuele Camerucci, MD (Kansas University Medical Center)
PRESENTER 		Dr. Camerucci has nothing to disclose.
Cole D. Stang Mr. Stang has nothing to disclose.
Pierpaolo Turcano, MD (Rush University Medical Center) Dr. Turcano has nothing to disclose.
Philip W. Tipton, MD Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Alzheimer's Tennessee. Dr. Tipton has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Charlotte County Medical Society, Inc.
James H. Bower, MD, MSc, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) The institution of Dr. Bower has received research support from Abbvie.
Bryan T. Klassen, MD (Mayo Clinic) The institution of Dr. Klassen has received research support from Insightec.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine) Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Rodolfo Savica, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.